Market Trends Wall Street firms say this obesity beneficiary is a buy, with one calling for more than 85% upsideBy admin8996erT0allFebruary 25, 2025 Within weeks of going public, Metsera is already starting to earn attention from Wall Street analysts due to its connection…
Market Trends Obesity drug developer Metsera files for $100M IPO (IPO:NYSEARCA)By admin8996erT0allJanuary 13, 2025 2d illustrations and photosMetsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M…
